CyTOF technology provides best-in-class deep immune profiling for longitudinal clinical research studies.
The high-parameter data provided by CyTOF® systems captures the complexity of the immune system, revealing often-unanticipated immune cell interactions. These results define the immune response and disease immunopathology and are helping investigators in both academics and the pharmaceutical industry to refine development of treatments and vaccines for better disease management.
As the first complete sample-to-answer solution for high-dimensional immune profiling of human PBMC and whole blood, the Maxpar® Direct™ Immune Profiling System provides the data quality and reproducibility required to capture the highly individual nature of immune response in health and disease.
Broad adoption by consortia and in clinical research studies
The Maxpar Direct Immune Profiling System has been adopted for use by multiple consortia and clinical research studies based on its ease of use and reproducibility lot-to-lot, run-to-run and site-to-site. Learn more about how this comprehensive and reliable approach to immune monitoring is reducing time to results and lowering cost for large studies.
CyTOF in the Cancer Immune Monitoring and Analysis Centers (CIMAC): Standardization and Harmonization
Holden Maecker, PhD
Professor of Microbiology and Immunology Director of the Human Immune Monitoring Center Stanford University
Chen, H.X. et al. “Network for biomarker immunoprofiling for cancer immunotherapy: Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC).” Clinical Cancer Research (2021): doi:10.1158/1078-0432.CCR-20-3241.
A complete immune monitoring solution with CyTOF: Ideal for pandemics and beyond
Frederik De Smet, MSc, PhD
University of Leuven, Belgium
Related clinical trial
Proven performance and reproducibility
Multiple studies have shown the reproducibility of the Maxpar Direct Immune Profiling System lot-to-lot, run-to-run and site-to-site.
Performance consistency across 11 lots of Maxpar® Direct™ Immune Profiling Assay™ tubes. Data available on request.
Multi-site studies using the Maxpar Direct Immune Profiling Assay
Bagwell, C.B. et al. “Multi-site reproducibility of a human immunophenotyping assay in whole blood and peripheral blood mononuclear cells preparations using CyTOF® technology coupled with Maxpar® Pathsetter™, an automated data analysis system.” Cytometry Part B Clinical Cytometry 98 (2020): 146–160.
The technical details: Populations, clones and workflows
Designed as a simple, single-tube workflow, the system brings together CyTOF technology on the CyTOF XT™ and Helios™ mass cytometry systems, a dry-format 30-marker antibody panel and automated Maxpar Pathsetter™ software so you can easily identify 37 immune cell populations with performance you can trust.
Get more details from the Maxpar Direct Immune Profiling flyer.
The 37 immune cell subsets identified using the Maxpar Direct Immune Profiling Assay and Maxpar Pathsetter software.
Single-tube antibody panel design. All antibody clones used in the kit are familiar and industry-proven.
Samples stained with the Maxpar Direct Immune Profiling Assay can be fixed, frozen and stored for analysis at a later time or at another location.
Customization lets you go even deeper
The Maxpar Direct Immune Profiling Assay was designed with customization in mind. While the assay provides excellent immune cell coverage, 14 or more additional markers can be added into the empty channels to support your unique study goals.
Download the Maxpar Direct Expansion Panels flyer to see details on the 6 panels that enable deeper profiling of multiple immune cell types including myeloid, B, T and NK cells.
Unless explicitly and expressly stated otherwise, all Fluidigm products are provided for Research Use Only, not for use in diagnostic procedures. For more information see www.fluidigm.com/legal/notices